- Home
- SGU vs CMPS Comparison
SGU vs CMPS Comparison
Compare SGU & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGU
- CMPS
- Stock Information
- Founded
- SGU 1995
- CMPS 2020
- Country
- SGU United States
- CMPS United Kingdom
- Employees
- SGU N/A
- CMPS N/A
- Industry
- SGU Other Specialty Stores
- CMPS Biotechnology: Pharmaceutical Preparations
- Sector
- SGU Consumer Discretionary
- CMPS Health Care
- Exchange
- SGU Nasdaq
- CMPS Nasdaq
- Market Cap
- SGU 445.9M
- CMPS 364.9M
- IPO Year
- SGU 1995
- CMPS 2020
- Fundamental
- Price
- SGU $11.85
- CMPS $4.34
- Analyst Decision
- SGU
- CMPS Strong Buy
- Analyst Count
- SGU 0
- CMPS 7
- Target Price
- SGU N/A
- CMPS $17.83
- AVG Volume (30 Days)
- SGU 44.7K
- CMPS 2.4M
- Earning Date
- SGU 08-12-2025
- CMPS 07-31-2025
- Dividend Yield
- SGU 6.32%
- CMPS N/A
- EPS Growth
- SGU 123.45
- CMPS N/A
- EPS
- SGU 1.78
- CMPS N/A
- Revenue
- SGU $1,803,079,000.00
- CMPS N/A
- Revenue This Year
- SGU N/A
- CMPS N/A
- Revenue Next Year
- SGU N/A
- CMPS N/A
- P/E Ratio
- SGU $6.66
- CMPS N/A
- Revenue Growth
- SGU 2.38
- CMPS N/A
- 52 Week Low
- SGU $10.11
- CMPS $2.25
- 52 Week High
- SGU $13.75
- CMPS $8.54
- Technical
- Relative Strength Index (RSI)
- SGU 52.03
- CMPS 56.52
- Support Level
- SGU $11.67
- CMPS $3.92
- Resistance Level
- SGU $12.20
- CMPS $4.78
- Average True Range (ATR)
- SGU 0.20
- CMPS 0.37
- MACD
- SGU 0.01
- CMPS 0.03
- Stochastic Oscillator
- SGU 39.66
- CMPS 65.63
About SGU Star Group L.P.
Star Group LP is a company engaged in providing home heating products and services to residential and commercial customers. The company offers heating oil and air conditioning equipment, as well as home security and plumbing services. The company also sells diesel fuel, gasoline, and home heating oil. Geographically, the company operates in U.S.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.